Adicet Bio, Inc. (ACET)
|52 Week Range||4.61-21.87|
|1y Target Est||-|
|DCF Unlevered||ACET DCF ->|
|DCF Levered||ACET LDCF ->|
|Debt / Equity||13.12%||Neutral|
Upgrades & Downgrades
Latest ACET news
Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates
9 May 2023
Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to earnings of $0.10 per share a year ago.
7 Biotech Stocks That Could Be the Next Big Thing
15 March 2023
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that c...
Adicet Bio: Searching For Upside In Cell Therapeutics
7 February 2023
Biotechs developing CAR-T cell therapies have seen their valuations plummet in 2022 - making them an intriguing speculative buy opportunity in 2023. This is a complex field characterized by study fail...
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
25 January 2023
Here is how Adicet Bio, Inc. (ACET) and AlloVir, Inc. (ALVR) have performed compared to their sector so far this year.
Down -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET)
30 December 2022
Adicet Bio, Inc. (ACET) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in r...
5 Stocks to Pop Surprise Returns From Secret Santa
22 December 2022
Adicet Bio (ACET), Enfusion (ENFN), Dillard's (DDS), First BanCorp. (FBP) and Hillenbrand (HI) could bring gifts of surprise returns from Secret Santa.
Adicet Bio, Inc. (ACET) Loses 47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
14 December 2022
Adicet Bio, Inc. (ACET) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings es...
Why The Adicet Bio (ACET) Stock Plummeted Over 35%
12 December 2022
The stock price of Adicet Bio (ACET) plummeted over 35% intraday today. This is why.
Adicet Bio shares fall as it shares clinical data about its CAR-T treatment candidate
12 December 2022
Adicet Bio's Inc. ACET, -13.13% stock tumbled about 38% in premarket trading on Monday after the company shared data from a Phase 1 clinical trial evaluating the company's investigational CAR-T therap...
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >